Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas

Breast

Volumn 21, Issue 3, 2012, Pages 354-360

  Gerhard, Renê ^a   Ricardo, Sara ^a   Albergaria, André ^a   Gomes, Madalena ^a   Silva, Alfredo Ribeiro ^b   Logullo, Ângela Flavia ^c   Cameselle Teijeiro, Jorge F ^d   Paredes, Joana ^a,e   Schmitt, Fernando ^a,e  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^e University of Porto   (Portugal)

Author keywords

Breast cancer; Claudin low subtype; Claudins; Metaplastic breast carcinoma

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CLAUDIN; CLAUDIN 1; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STEM CELL; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METAPLASTIC BREAST CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84862535875     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.03.001     Document Type: Article

References (44)

1. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
2. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76.
3. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
4. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. New Engl J Med 2006, 355:1253-1261.
5. Mineta K., Yamamoto Y., Yamazaki Y., Tanaka H., Tada Y., Saito K., et al. Predicted expansion of the claudin multigene family. FEBS Lett 2011, 585:606-612.
6. Turksen K., Troy T.C. Barriers built on claudins. J Cell Sci 2004, 117:2435-2447.
7. Morin P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65:9603-9606.
8. Lanigan F., McKiernan E., Brennan D.J., Hegarty S., Millikan R.C., McBryan J., et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 2009, 124:2088-2097.
9. Hewitt K.J., Agarwal R., Morin P.J. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006, 6:186.
10. Tse G.M., Tan P.H., Putti T.C., Lui P.C., Chaiwun B., Law B.K. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 2006, 59:1079-1083.
11. Elston CaE.O. The breast. systemic pathology 1998, vol. 13. Churchill Livinstone, 1-18.
12. Beatty J.D., Atwood M., Tickman R., Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg 2006, 191:657-664.
13. Sproul D., Nestor C., Culley J., Dickson J.H., Dixon J.M., Harrison D.J., et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A 2011, 108:4364-4369.
14. Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T., Nesland J.M., et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006, 49:10-21.
15. Ricardo S., Vieira A.F., Gerhard R., Leitão D., Pinto R., Cameselle-Teijeiro J.F., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011, 64:937-946.
16. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
17. Mylona E., Giannopoulou I., Fasomytakis E., Nomikos A., Magkou C., Bakarakos P., et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39:1096-1102.
18. Paredes J., Correia A.L., Ribeiro A.S., Albergaria A., Milanezi F., Schmitt F.C. P-cadherin expression in breast cancer: a review. Breast Cancer Res 2007, 9:214.
19. Sousa B., Paredes J., Milanezi F., Lopes N., Martins D., Dufloth R., et al. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol 2010, 25:963-974.
20. Lester T.R., Hunt K.K., Nayeemuddin K.M., Bassett R.L., Gonzalez-Angulo A.M., Feig B.W., et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 2011.
21. Wargotz E.S., Deos P.H., Norris H.J. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989, 20:732-740.
22. Koker M.M., Kleer C.G. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004, 28:1506-1512.
23. Teixeira M.R., Qvist H., Bohler P.J., Pandis N., Heim S. Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes Chromosomes Cancer 1998, 22:145-151.
24. Wada H., Enomoto T., Tsujimoto M., Nomura T., Murata Y., Shroyer K.R. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol 1998, 29:1324-1328.
25. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl. 1):61-70.
26. Polyak K., Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010, 2:a003244.
27. Martinez-Estrada O.M., Culleres A., Soriano F.X., Peinado H., Bolos V., Martinez F.O., et al. The transcription factors slug and snail act as repressors of claudin-1 expression in epithelial cells. Biochem J 2006, 394:449-457.
28. Morohashi S., Kusumi T., Sato F., Odagiri H., Chiba H., Yoshihara S., et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 2007, 20:139-143.
29. Blanchard A.A., Skliris G.P., Watson P.H., Murphy L.C., Penner C., Tomes L., et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 2009, 454:647-656.
30. Szasz A.M., Nyirady P., Majoros A., Szendroi A., Szucs M., Szekely E., et al. Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 2009, 105:716-722.
31. Soini Y., Tommola S., Helin H., Martikainen P. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch 2006, 448:52-58.
32. Sauer T., Pedersen M.K., Ebeltoft K., Naess O. Reduced expression of claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16:193-198.
33. Szasz A.M., Tokes A.M., Micsinai M., Krenacs T., Jakab C., Lukacs L., et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 2011, 28:55-63.
34. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033.
35. Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum Pathol 2004, 35:1531-1536.
36. Tokes A.M., Kulka J., Paku S., Szik A., Paska C., Novak P.K., et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005, 7:R296-R305.
37. Park D., Karesen R., Axcrona U., Noren T., Sauer T. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. APMIS 2007, 115:52-65.
38. Kulka J., Szasz A.M., Nemeth Z., Madaras L., Schaff Z., Molnar I.A., et al. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol Oncol Res 2009, 15:59-64.
39. D'Souza T., Agarwal R., Morin P.J. Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 2005, 280:26233-26240.
40. Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005, 115:1765-1776.
41. Boireau S., Buchert M., Samuel M.S., Pannequin J., Ryan J.L., Choquet A., et al. DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis 2007, 28:246-258.
42. Turksen K. Claudins and cancer stem cells. Stem Cell Rev 2011.
43. Tzelepi V.N., Tsamandas A.C., Vlotinou H.D., Vagianos C.E., Scopa C.D. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 2008, 21:22-30.
44. Turksen K., Troy T.C. Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 2011, 1816:73-79.